ABSTRACT: Sixty-six clinical P. aeruginosa isolates, 17 obtained from canine otitis specimens and 49 received from human patients with bloodstream infections, were collected between February 2007 and January 2008. The minimal inhibitory concentrations (MICs) of the antimicrobial agents of these isolates were determined. Multidrug resistance was common, with 23 (34.8%) isolates found to be ceftazidime resistant. To explore the mechanisms of ceftazidime resistance, PCR analyses were performed to detect drug-resistance genes. The prevalence rate of Ambler class A, B, and D β-lactamase genes were obtained, with bla TEM-1 100%, bla PSE-1 100%, bla OXA-2 96.2%, bla SHV-18 91.3%, bla OXA-17 78.3%, bla VIM-3 26.1%, bla OXA-10 21.7% and bla SHV-1 8.7%. An efflux inhibition assay with the PAβN compound was conducted. The ceftazidime resistance isolates were also tested by RT-qPCR to determine the mRNA expression levels of the oprM and ampC genes. Five (21.7%) of the ceftazidime resistance isolates appeared to overactivate the OprM efflux system. The ampD, ampE, and ampR genes and the ampC-ampR intergenic region were subsequently amplified and sequenced. Five (21.7%) of the ceftazidime resistance isolates from humans and canines had a point mutation in AmpR (Asp135-Asn, n = 3; Als194-Ser, n = 2), which induces AmpC overproduction from 10-to 80-fold. This study first reported ceftazidime resistance in P. aeruginosa from canine otitis specimens, which are closely related to ESBLs (50%), including the overproduction of AmpC (25%) and the OprM efflux system (25%). The ESBLs (100%) played an important role in all ceftazidime resistance isolates from humans, and either AmpC (21.1%) or OprM (21.1%) might be overexpressed within the same isolate. A human patient isolate (H307B) showed simultaneous expression of ESBLs, the OprM efflux system, and AmpC overproduction.
Pseudomonas aeruginosa causes septicemia and nosocomial infections in humans (El Amary et al., 2001; Berthelot et al., 2005) and otitis externa, pyoderma, wound infections and abscesses in canines (Griffin, 1993; Cole et al., 1998; Scott et al., 2001; Peterson et al., 2002) . Ceftazidime is an important and effective antimicrobial agent for the therapy of serious infections due to multidrug resistance in P. aeruginosa. A surge in ceftazidime resistance in human clinical isolates of P. aeruginosa results from the production of acquired β-lactamase, the constitutive overproduction of AmpC, or an activation of the MexAB-OprM or MexXY-OprM efflux systems (Lindberg et al., 1987; Li et al., 1994; Stapleton et al., 1995; Nordmann and Guibert, 1998; Aires et al., 1999; Kuga et al., 2000; Masuda et al., 2000; Livermore, 2002) . The molecular mechanism of canine ceftazidime resistance in P. aeruginosa isolates still requires further clarification. In this study, we attempt to elucidate the different ceftazidime resistance mechanisms between canine and human isolates of P. aeruginosa.
MATERIAL AND METHODS

Bacterial isolates and antimicrobial susceptibility test
This study included 66 isolates identified as P. aeruginosa by API 20NE (bioMérieux, Marcy l'Etoile, France). Seventeen were collected from canine otitis specimens in a veterinary teaching hospital, and 49 were collected from human patients with bloodstream infections in a number of hospital microbiology laboratories, between February 2007 and January 2008. Antimicrobial susceptibility tests followed the broth microdilution method of performance standards for antimicrobial susceptibility testing (CLSI, 2006) . The antimicrobial agents used were ciprofloxacin and enrofloxacin (Fluka Chemie, Buchs, Switzerland); ampicillin, aztreonam, ceftazidime, chloramphenicol, colistin, and gentamicin (Sigma Aldrich, St Louis, MO, USA); cefepime (Bristol-Myers Squibb, Hounslow, UK); and meropenem (Astra-Zeneca, Macclesfield, UK). Reference standards of Escherichia coli ATCC 25922 and P. aeruginosa ATCC 27853 were used as controls on each plate to determine minimal inhibitory concentrations (MICs). All bacteria were incubated in Mueller Hinton broth with the aforementioned antimicrobial agents under a variety of concentrations at 37°C for 16-18 hours. Bacterial growth was subsequently inspected via observation of turbidity.
Amplification and sequencing of β-lactamase genes
The detection of bla TEM , bla SHV , bla OXA , bla PER , bla VIM , bla IMP , bla SPM , bla VEB , bla GES and bla PSE type extended spectrum β-lactamases (ESBLs) in the ceftazidime resistance isolates was performed by PCR with the specific primers listed in Table 1 and under conditions described elsewhere (Gales et al., 2003; Weldhagen, 2004; Jiang et al., 2006; Strateva et al., 2007) . The total DNA of P. aeruginosa isolates was extracted using the InstaGene DNA Purification Matrix kit (Bio-Rad, CA, USA), as recommended by Bio-Rad. The target extracted DNA was amplified by the GeneAmp PCR system 9600 thermal cycler (Applied Biosystems, Foster City, CA). PCR products were cloned into cloning vector pCRII (Invitrogen Life Technologies, Paisley, UK) for DNA sequencing if unexpected sizes of the PCR products were found. All acquired DNA sequences were subjected to the method of Altschul et al. (1997) for comparison with the BLAST online search engine from GenBank at the National Center for Biotechnology Information at http://www.ncbi. nlm.nih.gov/blast.
Plasmid profile, plasmid DNA restriction length polymorphism, and Southern blot hybridization
To detect the prevalence rate of the bla SHV-18 gene, plasmid DNAs were prepared from the 23 ceftazidime resistance P. aeruginosa isolates. Plasmid DNA was extracted using the Qiagen Midi Kit (Qiagen, Courtaboeuf, France), digested with the PstI restriction enzyme (TaKaRa, Japan) and then analyzed in a 0.8% agarose gel. Southern blot hybridization was performed according to Sambrook et al. (1989) , in which digested plasmid DNA was transferred onto a Hybond N + nylone membrane (Nycomed Amersham plc, Buckinghamshire, UK) with a vacuum blotting system. The bla SHV-18 -specific probe from the PCR-generated amplicons of bla containing Klebsiella pneumonia ATCC 700603 was labeled with a PCR DIG-labeling kit (Roche Diagnostics GmbH, Mannheim, Germany). The membrane was pre-hybridized at 42°C for 1 h, and hybridization took place at 42°C for 24 h to denature the bla probe. Subsequently, the DIG-High Prime DNA labeling and detection system (Digoxigenin Labeling and Detection Kit; Roche Diagnostics, Mannheim, Germany) was used for signal detection.
Amplification and sequencing genes of the ampD, ampE and ampR, and ampR-ampC intergenic regions
To determine the presence of ampD and ampE in each isolate, the PCR procedures and conditions used were as follows: all amplifications were performed in 50 µl reactions containing DNA (2.5 µl), primers (50 pmol each), deoxynucleoside triphosphates (200µM), Taq DNA polymerase (1.25 U; Takara Biomedicals, Tokyo, Japan) and 5 μl of 10 × Taq polymerase buffer (500mM KCl, 100mM TrisHCl [pH 8.3], 15mM MgCl 2 , 0.1% gelatin). Cycling conditions included denaturation for 10 min at 95°C, amplification for 30 cycles of 30 s at 95°C, 1 min at 60°C for ampD and 57°C for ampE, and 1 min at 72°C, and extension for 10 min at 72°C. Amplification of ampR, including the ampR-ampC intergenic region in each isolate, was performed under the following PCR conditions: denaturation for 10 min at 94°C; amplification for 30 cycles of 1 min at 94°C, 1 min at 55°C, and 1 min at 72°C; and extension for 10 min at 72°C. A 20 µl aliquot of the PCR product was electrophoresed in a 1.0% agarose gel and stained with ethidium bromide (50 mg/l). Band sizes of 0.9 kb and 1.2 kb were defined as the ampD gene and the ampE genes. A size of 1.0 kb was defined as ampR including the ampR-ampC intergenic region. The remaining PCR products were purified using a PCR purification kit (Qiagen, Valencia, CA, USA) and were sequenced with PCR forward and reverse primers using the ABI PRISM Big Dye cycle sequencing ready reaction kit (Applied Biosystems, Foster City, CA, USA) and an ABI PRISM 3700 DNA Sequencer (Applied Biosystems, Foster City, CA, USA). The primers used are listed in Table 1 . DNA sequence data were analyzed as recommended by GenBank DNA sequences using the National Center for Biotechnology Information via the BLAST network service (Altschul et al., 1997) , and were subsequently compared with wild-type PAO1 sequences in GenBank, accession numbers X67095 (ampR), X54719 (ampR-ampC intergenic region), and AF082575 (ampD, ampE). The Clustal W method in the Multiple Sequence Alignment Program was used to align and compare the sequences.
RNA isolation
All ceftazidime-resistant P. aeruginosa isolates (n = 23) were incubated aerobically in LB (Luria Bertani) broth until mid-log phase. RNA was subsequently isolated with TRI Reagent (Molecular Research Center, Cincinnati, OH, USA). Eight micrograms of RNA from each isolate was treated for 1 hour with 8 units of RO1 RNase-free DNase (Promega, Madison, WI, USA) to eliminate DNA. The SuperScript III first-strand synthesis system (Invitrogen Life Technologies, Paisley, UK) was used to synthesize cDNA from total RNA, and random hexamers were used for RT-PCR.
Detection of ampC and oprM genes by real-time qPCR
The specific primers listed in Table 1 were used to amplify ampC and oprM genes in the iCycler iQ5 real-time detection system (Bio-Rad Laboratories) using Sybr Green iQ TM supermix (BioRad Laboratories). Thermal cycling conditions were as follows: 3 min at 95°C, 40 cycles of 10 s at 95°C, and 30 s at 58°C. Melting curves were then analyzed under the following conditions: the temperature was ramped to 95°C for 1 min, cooled to 58°C for 1 min at a slope of 20°C per second, followed by a 0.1°C per second rise in temperature up to 95°C. Triplicate PCR reactions were performed for each isolate. The rpoD housekeeping gene was used as an internal standard (Savli et al., 2003) , amplified in separate quantity PCR reactions to correct for differences in the mRNA recovery rate. The relative expression of ampC and oprM was assessed by the ΔΔC T method as described previously (Livak and Schmittgen., 2001) . P. aeruginosa ATCC 27853 was used as a control to calculate the ratio of ampC and oprM gene expression in three experiments for each isolate. To ensure the specific amplification acquired, 1% agarose gel electrophoresis and ethidium bromide staining was carried out to confirm the absence of additional PCR products.
Efflux pump inhibition test
All ceftazidime resistant P. aeruginosa isolates (n = 23) were tested for efflux pump inhibition. The ceftazidime MICs were determined by broth microdilution in the absence or presence of 50 mg/l PAβN (Sigma Aldrich, St Louis, MO, USA). The ceftazidime MICs decreased at least 4-fold in the presence of PAβN, likely due to overproduction of the efflux pumps as shown by the positive reaction in the efflux pump inhibition test (Mesaros et al., 2007) .
RESULTS AND DISCUSSION
All P. aeruginosa isolates from canine and human infections showed 100% resistance to ampicillin and chloramphenicol in this study, because the intrinsic AmpC β-lactamases and the MexAB-OprM efflux pump were expressed in virtually all isolates (Ziha-Zarifi et al., 1999; Masuda et al., 2000; Juan et al., 2005) . MICs at which 50% and 90% of the bacterial cells were inhibited (MIC 50 and MIC 90 ) and antimicrobial susceptibility profiles against antimicrobial agents are summarized in Table 2 . In the case of isolates from canine otitis externa In this study, 34.8% of the isolates (23/66) showed resistance to ceftazidime, 19 isolates from bacteremia patients and four isolates from canine otitis specimens, with MICs ranging from 32 to 256 mg/l (Table 3) . However, the pattern of ceftazidime resistance in P. aeruginosa isolates from humans has varied considerably in previous studies. Spencer (1996) found that 95% of isolates were sensitive to ceftazidime, Panayotis et al. (1998) reported 15% isolate resistance, Shawar et al. (1999) 11.1%, Mueller-Premru and Gubina (2000) 9.1%, and De Champs et al. (2002) 6%. In contrast, Seol et al. (2002) found that 19.7% of P. aeruginosa isolated from canines was resistant to ceftazidime. The present study revealed that resistance to ceftazidime was 38.8% (17/49) for human isolates and 23.5% (4/17) for canine isolates. To understand the discrepancies among previous reports, all 23 ceftazidime resistance P. aeruginosa isolates were studied to characterize the molecular mechanisms of resistance against ceftazidime.
The ceftazidime resistance of P. aeruginosa isolates was also related to Ambler class A β-lactamases such as bla TEM -, bla SHV -, bla VEB -, bla PER -, or bla GEStype; class B β-lactamases such as bla IMP -, bla VIM -, or bla SPM -type; and class D β-lactamases such as bla OXA -type, all of which were encountered in this study. The 23 ceftazidime resistance isolates were subjected to PCR analyses using specific primers for class A, B and D β-lactamase genes. The results revealed the following frequencies: bla TEM-1 100%, bla PSE-1 100%, bla OXA-2 96.2%, bla SHV-18 91.3%, bla OXA-17 78.3%, bla VIM-3 26.1%, bla OXA-10 21.7% and bla SHV-1 8.7%. Conversely, bla VEB -, bla GES -, bla PER -, bla IMP -, and bla SPM -type ESBLs genes were not detected among these isolates (Table 3) .
In this study, bla SHV18 was the most common SHV-type ESBL coexisting with bla TEM-1 , bla PSE-1 , bla OXA group II (OXA-2), bla OXA10 or bla in the ceftazidime resistance isolates of P. aeruginosa. In the human isolates, the most prevalent ESBLs in P. aeruginosa are bla and bla in Taiwan (Yu et al., 2006) . However, in the current study, we found that the bla SHV-18 -producing member of P. aeruginosa occurred in both canine and human isolates. Twenty-one isolates were positive for the bla SHV-18 gene (Table 3) , localized in plasmids ranging from 35 to 50 kb, as detected by Southern blot hybridization. Two isolates (NTD 91 and NTD106) of ceftazidime resistance P. aeruginosa from canines carried bla . The clinical history of the canine isolates did not include the use of any expanded-spectrum cephalosporins, though the canines might have been previously treated by other clinical surgeons. The OXA-10 derivatives confer greater resistance to ceftazidime than to cefepime. Among the extended spectrum derivatives of OXA-10, the OXA-11, -14, and -16 derivatives confer a high level of resistance to ceftazidime (MIC > 128 mg/l). By contrast, OXA-10 and OXA-17 has minimal effects on the MIC of ceftazidime. In this study, all 23 ceftazidime resistance isolates produced OXA-10 or -17, and showed marginal resistance (Strateva et al., 2007) . In this study, the human isolates of H62B, H236B, H253B, H270B, H468B, and H471B produced a bla VIM-3 metallo-β-lactamase and conferred increased resistance to ceftazidime (MICs, 32-256 mg/l). The bla VIM -positive isolates showed consistent high-level resistance to almost all broadspectrum cephalosporines, including ceftazidime and cefoperazone-sulbactam (MICs, ≥ 128 mg/l) (Senda et al., 1996; Yan et al., 2001) .
The presence of mutations responsible for the AmpC resistance phenotypes was subsequently investigated by PCR, and the genes for ampD, ampE, ampR as well as the ampC-ampR intergenic region were sequenced for the 23 ceftazidime resistance isolates. None of the resistance isolates contained mutations in the ampC-ampR intergenic region compared with their isogenic susceptible isolates. However, 23 ceftazidime resistance isolates had DNA mutations in the ampD structural gene, resulting in the substitution of nine amino acids at positions 10 (Val to Gly), 11 (Arg to Leu), 44 (Gln to His), 118 (Glu to Gly), 136 (Ala to Val), 148 (Gly to Ala), 174 (Trp to Cys), 175 (Ser to Leu) and 183 (Asp to Tyr) ( Table 4 ). In the ampR structural gene, seven amino acids differed at positions 12 (Ala to Arg), 114 (Glu to Ala), 135 (Asp to Asn), 194 (Ala to Ser), 237 (Gly to Ala), 283 (Gly to Glu), and 288 (Val to Arg) ( Table 3 ). In the ampE structural gene, eight amino acid changes were detected at positions 20 (Arg to Gln), 23 (Gln to Pro), 33 (Ser to Gly), 34 (Leu to Gln), 69 (Ser to Pro), 122 (Ile to Val), 129 (Glu to Asp), and 136 (Gly to Ser) ( Table 5) .
Many studies have shown that ceftazidime resistance isolates from humans are characterised by the overproduction of AmpC or OprM (Campbell et al., 1997; Li et al., 2000; Masuda et al., 2000; Bagge et al., 2002; Livermore et al., 2002; Henrichfreise et al., 2007; Tam et al., 2007) . RT-qPCR was performed for quantitative analysis of mRNA expression of the ampC and oprM genes. Total cellular mRNA was prepared from the 23 P. aeruginosa isolates. The results for the relative expression of the ampC and oprM genes are summarized in Table 3 . Group 1 isolates were characterized by increased ampC expression. Three ceftazidime resistance isolates (H56B, H64B, H131B from humans) were char- acterized by a point mutation in AmpR (Asp135 -Asn), which caused a 37.80-to 80.20-fold increase in ampC mRNA levels, as compared to the levels in P. aeruginosa ATCC 27853 (Table 3 ). The other two isolates (NTD 121 from canine; H62B from human) from Group 1 also demonstrated a point mutation in AmpR (Als194 -Ser), which resulted in a 10.45-to 12.70-fold overproduction of AmpC (Table 3) . A novel amino acid substitution in position 194 is thought to have caused the overexpression of ampC. Bratu et al. (2007) have demonstrated that increased ampC expression is associated with major deletions that affect ampD, and Langaee et al. (2000) have shown that mutations within the structural gene of ampD can lead to ampC overexpression. These studies also found that increased β-lactam MICs in organisms with inducible ampC and ampE genes can modulate ampC repression in hyperproducing strains in the absence of inducers. Nevertheless, Bratu et al. (2007) emphasize that most of their 33 clinical isolates had one or two amino acid substitutions involving ampD and ampE, which do not seem to affect expression of ampC. A variety of limited levels of ampC expression were found from the isolates of ampD mutations (Table 4) and ampE mutations (Table 5) , although a few isolates had 80.2 (H64B), 12.7 (H62D) and 10.45 (NTD121) fold-difference for ampD mutations (Table 4) ; and 25.55 (H307B) and 12.7 (H62B) for ampE mutations (Table 5) . When comparing the same isolates for ampR effect on the levels of ampC expression (Table 3 ) with the effect of ampD (Table 4) and ampE (Table 5) , we attribute most of this AmpC overproduction to the point mutation in AmpR even if there was observed a combined effect of ampR, ampD and ampE in the same isolates. In the present study, the multiple mutations observed in AmpD and AmpE require further study in order to explain the differences in transcription levels, consistent with the report of Bratu et al. (2007) . Moreover, these results show that ceftazidime resistance mediated by AmpC overproduction could be attributed to mutations in the ampR gene.
Group 2 isolates were characterized by increased expression of OprM. The transcriptional level of oprM is shown in Table 3 . Aires et al. (1999) reported up-regulation of the expression of the efflux systems MexAB and MexXY in the P. aeruginosa strains. Five of the 23 (21.7%) ceftazidime resistance isolates, one isolate (NTD 52) from canine and four isolates (H61B, H270B, H307B, and H253B) from humans, showed over-expression of oprM mRNA, which compared with that in P. aeruginosa ATCC 27853, ranged between a 3.12-to 3.95-fold increase. The overproduction of OprM was absent in ciprofloxacin (MIC 0.5 mg/l) and meropenem (MIC 1 mg/l) resistance in canine isolate (NTD 52), but it was detected in very common resistance isolates (ciprofloxacin MIC 16-64 and meropenem MIC 32 mg/l), enrofloxacin, aztreonam, gentamicin, and chloramphenicol in human isolates (Table 3) . The results showed that overproduction of OprM increased the MICs of fluoroquinolones, aminoglycosides and aztreonam, consistent with findings described elsewhere (Li et al., 2000; Masuda et al., 2000) . The efflux pump inhibition assay in the absence or presence of the efflux inhibitor PAβN, as shown in Table 3 , showed a significant decrease (8-to 16-fold) in ceftazidime MIC upon addition of PAβN to Group 2. For Group 1 and 3, resistance to ceftazidime was found uniquely in the presence of PAβN. In the present study, 21.7% (5/23) of the ceftazidime-resistant P. aeruginosa isolates were related to overproduction of the drug efflux pump. These results indicate that the clinical use of β-lactams and/or other antimicrobial agents as therapy for both canines and humans might impose a strong selective pressure for the emergence of resistant bacteria.
